SureTrader
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilKahuna, BooDog, sox040713, Astavakra, Matagordaville, scottsmith
Search This Board: 
Last Post: 1/16/2018 6:05:52 PM - Followers: 741 - Board type: Free - Posts Today: 129

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

MILESTONES:


Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

SureTrader
IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Amended Statement of Ownership (sc 13g/a) 01/11/2018 04:35:53 PM
IPIX News: Statement of Changes in Beneficial Ownership (4) 12/27/2017 03:08:40 PM
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) 11/13/2017 10:03:05 AM
IPIX News: Quarterly Report (10-q) 11/08/2017 04:04:57 PM
IPIX News: Notice of Effectiveness (effect) 09/22/2017 06:02:17 AM
PostSubject
#211306  Sticky Note Chill Off! Data looks good! PlentyParanoid 01/03/18 12:19:54 PM
#211222  Sticky Note Bottom Line noretreat 01/03/18 07:43:11 AM
#211057  Sticky Note IPIX Milestones, Clinical Trials, Recent Articles, Corporate Overview, Patent sox040713 01/01/18 09:21:12 PM
#210140  Sticky Note A must read to due diligence for any tryz 12/27/17 10:48:29 AM
#200091  Sticky Note IPIX Clinical Trial Timelines sox040713 10/14/17 08:13:18 PM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#213095   If only he had all these options to TheDane 01/16/18 06:05:52 PM
#213094   I’m not. I believe Leo wants everything laid groton68 01/16/18 06:03:47 PM
#213093   You're confusing partnership with company buyout. frrol 01/16/18 05:57:43 PM
#213092   Leo thumping the BRI platform untohim 01/16/18 05:49:25 PM
#213091   FINRA short sales of IPIX AlanC 01/16/18 05:44:29 PM
#213090   Again...always Aspire to you, however they only sold DaubersUP 01/16/18 05:15:14 PM
#213089   Jan 2018 Sonis OM Rvw Article (Indeed KMBJN - slcimmuno 01/16/18 05:06:12 PM
#213088   I think so, too. The only one of PlentyParanoid 01/16/18 04:44:35 PM
#213087   Finally - It is all clear now. They PlentyParanoid 01/16/18 04:41:17 PM
#213086   I believe Galera already has funding partners. kfcyahoo 01/16/18 04:41:04 PM
#213085   Well, incidence numbers do look good - about PlentyParanoid 01/16/18 04:38:32 PM
#213084   They need both the OM and P reports groton68 01/16/18 04:35:40 PM
#213083   In coming weeks, we look forward to advancing frrol 01/16/18 04:26:36 PM
#213082   Watch you will see Clay Trader show up septmike09 01/16/18 04:15:49 PM
#213081   Those were pump and dumps. Why do you septmike09 01/16/18 04:08:55 PM
#213080   Biotechs pop on anticipation. Everyone knows that. scottsmith 01/16/18 04:06:28 PM
#213079   DID Galera Therapeutics present their supposedly GREAT OM runninggirl2016 01/16/18 04:06:10 PM
#213078   Rdun88 Now for some offers. Echo20 01/16/18 04:04:58 PM
#213077   Ok, clear. And the implication for our B-OM's frrol 01/16/18 04:02:10 PM
#213076   A deal is in the works. coming out septmike09 01/16/18 04:01:57 PM
#213075   I completely agree. if something was in MXAMDUD 01/16/18 04:00:06 PM
#213074   ffrol, I have a theory that Kepivance's blood cancer PlentyParanoid 01/16/18 03:59:10 PM
#213073   Simply not true. This is Bio Tech. they septmike09 01/16/18 03:53:02 PM
#213072   Precisely. But then our share price should scottsmith 01/16/18 03:50:17 PM
#213071   I shorted at .68. Will cover at 5.00. septmike09 01/16/18 03:45:10 PM
#213070   i have my doubts on that unless it MXAMDUD 01/16/18 03:44:31 PM
#213069   There is no down on a deal. It septmike09 01/16/18 03:42:36 PM
#213068   GC4419 Phase I results are available here, with KMBJN 01/16/18 03:41:42 PM
#213067   You said: “How can it adjust when nobody knows scottsmith 01/16/18 03:41:33 PM
#213066   We have only heard what Leo has said. septmike09 01/16/18 03:41:24 PM
#213065   Yes, Plenty. The mean duration of even the frrol 01/16/18 03:39:17 PM
#213064   Why would it go down? They would be septmike09 01/16/18 03:38:43 PM
#213063   we've heard 'in a few weeks' forever from MXAMDUD 01/16/18 03:36:45 PM
#213062   Or down we go if upfront cash is scottsmith 01/16/18 03:35:51 PM
#213061   The reality is there are no traders trading septmike09 01/16/18 03:28:44 PM
#213060   Echo, The science is strong, what's holding development Rdunn88 01/16/18 03:13:52 PM
#213059   that is because Leo has no trust from MXAMDUD 01/16/18 03:00:55 PM
#213058   So much for the impact of todays PR. JTORENCE 01/16/18 02:56:24 PM
#213057   I Smell Fish Market. But start is with relevance. PlentyParanoid 01/16/18 02:54:37 PM
#213056   Rdunn88 A very positive post from you. Must mean something. Echo20 01/16/18 02:48:45 PM
#213055   CallmeCrazy May your estimates be completed. Echo20 01/16/18 02:38:47 PM
#213054   IPIX mgmt has already expressed their intent to CallMeCrazy 01/16/18 02:13:43 PM
#213053   Large fake asks like that are usually seen DoubleJ23 01/16/18 02:07:45 PM
#213052   and we sit at .72. all these MXAMDUD 01/16/18 01:51:52 PM
#213051   From one paragraph of the PR. Citrati 01/16/18 01:23:49 PM
#213050   70k ask at .73? Couldn’t Aspire wait until Rdunn88 01/16/18 01:18:13 PM
#213048   Yes, guessing. TheDane 01/16/18 01:07:22 PM
#213047   CallmeCrazy Thank you. Echo20 01/16/18 01:06:31 PM
#213046   YEAH! He just wants to please the "LOYAL" shareholders. Blue Fin 01/16/18 01:05:55 PM
#213045   Most here are doing the same - guessing Amatuer17 01/16/18 01:02:11 PM
PostSubject